CNTF Gene

CNTF Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CNTF</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ciliary Neurotrophic Factor</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.1</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding gene</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1270</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>118425</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000261349</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P26441</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>IL-6 family of cytokines</td>
</tr>
<tr>
<td class="label">Receptor Complex</td>
<td>CNTFRα + gp130 + LIFRβ</td>
</tr>
<tr>
<td class="label">Major Pathways</td>
<td>JAK/STAT3, MAPK/ERK, PI3K/Akt</td>
</tr>
<tr>
<td class="label">Primary Disease Links</td>
<td>ALS, Alzheimer's Disease, Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">16 edges</a></td>
</tr>
</table>

CNTF Gene

Introduction

CNTF Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CNTF</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ciliary Neurotrophic Factor</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.1</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding gene</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1270</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>118425</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000261349</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P26441</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>IL-6 family of cytokines</td>
</tr>
<tr>
<td class="label">Receptor Complex</td>
<td>CNTFRα + gp130 + LIFRβ</td>
</tr>
<tr>
<td class="label">Major Pathways</td>
<td>JAK/STAT3, MAPK/ERK, PI3K/Akt</td>
</tr>
<tr>
<td class="label">Primary Disease Links</td>
<td>ALS, Alzheimer's Disease, Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">16 edges</a></td>
</tr>
</table>

CNTF Gene

Introduction

Ciliary Neurotrophic Factor (CNTF) is a neuroprotective cytokine belonging to the interleukin-6 (IL-6) family of cytokines. Originally discovered for its ability to support the survival of chick ciliary ganglion neurons in vitro, CNTF has emerged as a critical neuroprotective factor with broad therapeutic potential for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD).[@sendtner1992]

Unlike classical neurotrophins such as NGF and BDNF, CNTF is not a target-derived survival factor during development but rather functions as an "injury-related" neuroprotective factor. CNTF is expressed predominantly in astrocytes and is stored intracellularly rather than secreted via the classical secretory pathway. Its release is triggered by cellular injury or stress, making it part of the endogenous neuroprotective response to neural damage.

Molecular Biology

Gene Structure and Expression

The CNTF gene is located on chromosome 11q13.1 and encodes a 200-amino acid protein with a molecular weight of approximately 23 kDa. The gene structure is relatively simple, consisting of two exons separated by a single intron. CNTF is highly conserved across mammalian species, with human and mouse CNTF sharing significant sequence homology.

Expression pattern:

• Central nervous system: Primarily expressed in [astrocytes](/entities/astrocytes) throughout the brain and spinal cord
• Peripheral nervous system: Expressed in Schwann cells and olfactory ensheathing cells
• Non-neural tissues: Low-level expression in heart, skeletal muscle, kidney, and liver
• Induction: Expression increases in response to injury, inflammation, and hypoxia

Protein Structure

CNTF adopts a four-helix bundle structure characteristic of the IL-6 family cytokines. The protein consists of:

• N-terminal region: Important for receptor binding specificity
• Core four-helix bundle: Mediates interaction with the CNTFRα receptor subunit
• C-terminal region:volved in receptor complex formation

Receptor Signaling

Tripartite Receptor Complex

CNTF signals through a heterotrimeric receptor complex consisting of three subunits:[@stahl1994]

The assembly of this tripartite receptor is essential for signal transduction. CNTF first binds to CNTFRα, then recruits gp130 and LIFR to form a signaling-competent complex.

Signaling Pathways

Upon receptor activation, CNTF triggers multiple downstream signaling cascades:[@ip1993]

JAK/STAT3 Pathway (Primary)

• Janus kinases (JAK1, JAK2) are associated with gp130 and LIFR cytoplasmic domains
• Activation leads to STAT3 phosphorylation and dimerization
• Phosphorylated STAT3 translocates to the nucleus
• STAT3 target genes include:
• SOCS3: Negative feedback regulator
• BCL-2 family anti-apoptotic proteins
• GFAP: Astrocyte differentiation marker
• Neuronal survival genes

MAPK/ERK Pathway

• Ras activation follows receptor engagement
• MEK phosphorylation activates ERK1/2
• ERK translocates to nucleus to phosphorylate transcription factors
• Promotes neuronal differentiation and process outgrowth
• Cross-talk with STAT3 pathway

PI3K/Akt Pathway

• Activation occurs through recruitment of PI3K to phosphorylated receptors
• Akt phosphorylation mediates anti-apoptotic effects
• Key targets include:
• BAD: Phosphorylation inhibits pro-apoptotic function
• GSK-3β: Inhibition promotes cell survival
• FOXO transcription factors: Nuclear exclusion

Comparison with Other Neurotrophins

| Property | CNTF | NGF | BDNF |
|----------|------|-----|-----|
| Protein Family | IL-6 cytokine | Neurotrophin | Neurotrophin |
| Receptor | CNTFRα + gp130 + LIFR | TrkA + p75NTR | TrkB + p75NTR |
| Primary Pathway | JAK/STAT3 | PI3K/Akt, MAPK | PI3K/Akt, MAPK |
| Release Mechanism | Injury-induced | Constitutive/activity-dependent | Activity-dependent |
| CNS Expression | Astrocytes | Neurons | Neurons |

Neuroprotective Mechanisms

CNTF exerts neuroprotection through multiple, overlapping mechanisms:

1. Anti-Apoptotic Effects

CNTF potently inhibits [apoptosis](/mechanisms/apoptosis) in various neuronal populations:[@yang2002]

• Upregulation of BCL-2 and BCL-XL
• Inhibition of caspase-3 activation
• Prevention of mitochondrial cytochrome c release
• Activation of survival-promoting Akt signaling

2. Anti-Inflammatory Effects

CNTF modulates neuroinflammation through:[@albrecht2007]

• Suppression of microglial activation
• Reduction in pro-inflammatory cytokine production (IL-1β, TNF-α)
• Enhancement of anti-inflammatory cytokine expression
• Modulation of astrocyte reactivity

3. Excitoprotection

CNTF protects neurons against excitotoxic injury:[@kano1998]

• Downregulation of glutamate receptor expression
• Enhancement of calcium buffering capacity
• stabilization of mitochondrial function

4. Metabolic Support

CNTF enhances neuronal metabolic capacity:

• Increased glucose transporter expression
• Enhancement of mitochondrial function
• Boosted ATP production
• Improved neuronal resilience to metabolic stress

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

CNTF has been extensively studied in ALS due to its potent motor neuron protective effects:[@dittrich1996]

Pathological findings:

• CNTF levels reduced in ALS patient spinal cord
• Motor neurons show decreased CNTFRα expression
• Astrocytic CNTF response impaired in ALS

• Recombinant CNTF protein delivery (clinical trials)
• AAV-mediated CNTF gene therapy
• Cell-based CNTF delivery (encapsulated cells)
• Combined CNTF/GDNF approaches

• CNTF trials in 1990s showed modest effects
• Systemic administration limited by side effects (weight loss, cough)
• Current focus on direct CNS delivery methods

Alzheimer's Disease

CNTF provides multiple protective effects relevant to AD:[@weishaupt2002]

Mechanisms:

• Protection of hippocampal neurons from [amyloid-beta](/proteins/amyloid-beta) toxicity
• Attenuation of tau phosphorylation through Akt/GSK-3β signaling
• Preservation of synaptic function and plasticity
• Suppression of neuroinflammation
• Enhancement of cholinergic neuron survival

• AAV-CNTF delivery to basal forebrain
• Combined amyloid-targeted and CNTF approaches
• Stem cell-based CNTF delivery

Parkinson's Disease

CNTF protects dopaminergic neurons:[@escott1998]

Models:

• MPTP-induced parkinsonism
• 6-OHDA lesion models
• α-Synuclein overexpression models

• Protection of substantia nigra dopaminergic neurons
• Preservation of striatal dopamine terminals
• Enhancement of tyrosine hydroxylase expression
• Anti-apoptotic effects in dopaminergic cells

• AAV-CNTF to striatum and substantia nigra
• Encapsulated cell therapy
• Combined approaches with GDNF

Other Neurodegenerative Conditions

Huntington's Disease:

• Protection of striatal medium spiny neurons
• Improvement in motor function in models

• Promotion of oligodendrocyte precursor differentiation
• Remyelination potential
• Anti-inflammatory effects

• Reduction in infarct size
• Promotion of neurogenesis
• Enhancement of angiogenesis

• Protection of photoreceptor neurons
• Clinical trials with encapsulated cell therapy (NT-501)
• Preservation of visual acuity

Therapeutic Development

Delivery Methods

CNTF delivery to the CNS faces significant challenges due to the blood-brain barrier (BBB):

| Method | Advantages | Limitations | Status |
|--------|-------------|--------------|--------|
| Recombinant protein | Well-characterized | Poor BBB penetration | Preclinical |
| AAV gene therapy | Long-term expression | Immune response | Clinical trials |
| Encapsulated cells | Controlled release | Invasive implantation | Clinical trials |
| Neural stem cells | Targeted delivery | Tumor risk | Preclinical |

Gene Therapy Vectors

AAV-mediated CNTF delivery has shown promise:[@zywitza2018]

• AAV2/9 serotypes effective for CNS transduction
• Promoters for cell-type specificity (GFAP for astrocytes, synapsin for neurons)
• Regulation of expression (tet-on systems)
• Safety considerations for clinical development

Clinical Trials

Historical trials:

• CNTF dose escalation studies (1990s)
• Limited by systemic side effects
• ALS clinical trials showed modest neurochemical changes

• AAV-CNTF for PD (preclinical/early clinical)
• Encapsulated cell therapy for retinitis pigmentosa (completed trials)
• Stem cell-derived CNTF delivery (preclinical)

Challenges and Solutions

| Challenge | Solution Approach |
|-----------|----------------|
| BBB penetration | Direct CNS delivery (intracerebral, intrathecal) |
| Side effects | Targeted delivery, regulated expression |
| Immune response | Novel serotypes, immunosuppression |
| Optimal dosing | Regulated expression, encapsulated delivery |
| Tumor risk (cells) | Suicide gene safety switches |

Animal Models

CNTF Knockout Mice

CNTF knockout mice are viable but show interesting phenotypes:

Phenotypic characteristics:

• Mild motor neuron loss
• Reduced response to nerve injury
• Impaired oligodendrocyte function

• Astrocyte-specific deletion
• Motor neuron-specific studies
• Learning and memory deficits

CNTF Overexpression Models

Transgenic overexpression:

• Enhanced neuroprotection
• Improved functional recovery
• Rescue in ALS models

• AAV-CNTF delivery
• Cell-based expression
• Inducible systems

Therapeutic Targets

CNTF Receptor Agonists

| Compound | Mechanism | Stage | Notes |
|----------|-----------|-------|-------|
| CNTF protein | Receptor agonist | Clinical | Limited by side effects |
| CNTFRα agonists | Soluble receptor | Preclinical | Enhanced specificity |
| Small molecule | TrkB/STAT3 activation | Research | Oral delivery |

Delivery Approaches

• Recombinant CNTF
• Sustained release formulations

• AAV vectors
• Non-viral delivery

• Encapsulated cells
• Stem cell delivery

• CNTF + GDNF
• CNTF + neurotrophins

Genetic Studies

CNTF Polymorphisms

• Promoter variants
• Coding variants
• Association with ALS risk
• Effect on therapeutic response

Clinical Associations

• ALS phenotypic modifiers
• ALS progression rates
• Therapeutic response predictors

Cross-Links

• [Ciliary Neurotrophic Factor](/proteins/ciliary-neurotrophic-factor) — protein information
• [JAK/STAT3 Signaling Pathway](/mechanisms/jak-stat-signaling)
• [Neurotrophin Signaling in Neurodegeneration](/mechanisms/neurotrophin-signaling)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Astrocytes in Neurodegeneration](/entities/astrocytes)
• [Motor Neuron Diseases](/mechanisms/motor-neuron-disease)

External Links

• [NCBI Gene: CNTF](https://www.ncbi.nlm.nih.gov/gene/1270)
• [UniProt: CNTF](https://www.uniprot.org/uniprot/P26441)
• [Ensembl: CNTF](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000261349)
• [Allen Human Brain Atlas: CNTF expression](https://human.brain-map.org/microarray/search/show?search_term=CNTF)
• [ClinicalTrials.gov: CNTF](https://clinicaltrials.gov/search?term=CNTF)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CNTF Gene discovered through SciDEX knowledge graph analysis: